Financial reports
20-F
2022 FY
Annual report (foreign)
28 Mar 23
20-F
2021 FY
Annual report (foreign)
27 Apr 22
20-F
2020 FY
Annual report (foreign)
8 Mar 21
20-F
2019 FY
Annual report (foreign)
18 Mar 20
20-F
2018 FY
Annual report (foreign)
29 Mar 19
20-F/A
2017 FY
Annual report (foreign) (amended)
23 May 18
20-F
2017 FY
Annual report (foreign)
24 Apr 18
Current reports
6-K
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
21 Feb 24
6-K
PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024
19 Jan 24
6-K
PHAXIAM Provides Business and Financial Update
16 Nov 23
6-K
Current report (foreign)
25 Oct 23
6-K
PHAXIAM Therapeutics announces high coverage performance of its two anti-Staphylococcus aureus phages over clinical strains
11 Oct 23
6-K
PHAXIAM Therapeutics and Vetophage Announce
5 Oct 23
6-K
I.Certification of the Person Responsible for the Half-year Financial Report
26 Sep 23
6-K
Current report (foreign)
21 Sep 23
6-K
PHAXIAM Therapeutics announces the completion of its reverse share split
18 Sep 23
6-K
Current report (foreign)
15 Sep 23
Registration and prospectus
15F-12B
Securities registration termination (foreign)
11 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Mar 24
POS AM
Prospectus update (post-effective amendment)
4 Mar 24
25
Voluntary exchange delisting
1 Mar 24
424B3
Prospectus supplement
29 Jun 23
F-X
Appointment of agent for service of process by issuers registering securities
24 May 23
Proxies
No filings
Other
EFFECT
Notice of effectiveness
6 Mar 24
EFFECT
Notice of effectiveness
30 Sep 21
CORRESP
Correspondence with SEC
28 Sep 21
UPLOAD
Letter from SEC
28 Sep 21
CT ORDER
Confidential treatment order
15 Jun 21
EFFECT
Notice of effectiveness
13 Oct 20
CORRESP
Correspondence with SEC
7 Oct 20
UPLOAD
Letter from SEC
28 Sep 20
EFFECT
Notice of effectiveness
31 Jul 19
CORRESP
Correspondence with SEC
29 Jul 19
Ownership
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 23
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 23
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
23 Dec 22
SC 13G
ARMISTICE CAPITAL, LLC
15 Feb 22
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 22
SC 13G
BIOTECHNOLOGY VALUE FUND L P
10 Mar 21
SC 13D/A
BIOTECHNOLOGY VALUE FUND L P
29 Jan 21
SC 13D/A
BIOTECHNOLOGY VALUE FUND L P
12 Jan 21
SC 13D/A
BIOTECHNOLOGY VALUE FUND L P
13 Oct 20
SC 13D/A
Erytech Pharma S.A.
8 Nov 18